Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease

A phase III randomized, placebo-controlled, double-blind study of the gardos channel blocker senicapoc (ICA-17043)

Kenneth Ataga, Marvin Reid, Samir K. Ballas, Zahida Yasin, Carolyn Bigelow, Luther St James, Wally R. Smith, Frederic Galacteros, Abdullah Kutlar, James H. Hull, Jonathan W. Stocker

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Red blood cell (RBC) hydration is regulated in part by the Ca2+-activated K+ efflux (Gardos) channel. Senicapoc selectively blocks potassium efflux through the Gardos channel, reducing RBC dehydration and haemolysis, and increasing haemoglobin levels in sickle cell disease (SCD). This randomized, placebo-controlled trial was designed to determine the safety and clinical efficacy of senicapoc in SCD patients. One hundred and forty-five patients were randomized to receive senicapoc and 144 patients to receive placebo for 52weeks. Consistent with a previous study, patients in the senicapoc group had significantly increased haematocrit, haemoglobin, and decreased numbers of both dense erythrocytes and reticulocytes when compared to the placebo group. The unblinded Data Monitoring Committee terminated this study early due to a lack of efficacy when it determined that, despite improvements in anaemia and haemolysis, no significant improvement in the rate of sickle cell painful crises was observed in patients treated with senicapoc compared to those on placebo (0·38 vs. 0·31, respectively). Comparisons of the times to first, second and third crises between the senicapoc and placebo groups were not statistically significant. Nausea and urinary tract infections occurred more frequently in the senicapoc group than placebo. Serious adverse events were similar in the two groups.

Original languageEnglish (US)
Pages (from-to)92-104
Number of pages13
JournalBritish Journal of Haematology
Volume153
Issue number1
DOIs
StatePublished - Apr 1 2011
Externally publishedYes

Fingerprint

Erythrocyte Aging
Sickle Cell Anemia
Hemolysis
Double-Blind Method
Placebos
Erythrocytes
Hemoglobins
Clinical Trials Data Monitoring Committees
Reticulocytes
senicapoc
Dehydration
Hematocrit
Urinary Tract Infections
Nausea
Anemia
Potassium
Randomized Controlled Trials
Safety

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease : A phase III randomized, placebo-controlled, double-blind study of the gardos channel blocker senicapoc (ICA-17043). / Ataga, Kenneth; Reid, Marvin; Ballas, Samir K.; Yasin, Zahida; Bigelow, Carolyn; James, Luther St; Smith, Wally R.; Galacteros, Frederic; Kutlar, Abdullah; Hull, James H.; Stocker, Jonathan W.

In: British Journal of Haematology, Vol. 153, No. 1, 01.04.2011, p. 92-104.

Research output: Contribution to journalArticle

Ataga, Kenneth ; Reid, Marvin ; Ballas, Samir K. ; Yasin, Zahida ; Bigelow, Carolyn ; James, Luther St ; Smith, Wally R. ; Galacteros, Frederic ; Kutlar, Abdullah ; Hull, James H. ; Stocker, Jonathan W. / Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease : A phase III randomized, placebo-controlled, double-blind study of the gardos channel blocker senicapoc (ICA-17043). In: British Journal of Haematology. 2011 ; Vol. 153, No. 1. pp. 92-104.
@article{dc5688c87235421b9c153c59cde7767f,
title = "Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: A phase III randomized, placebo-controlled, double-blind study of the gardos channel blocker senicapoc (ICA-17043)",
abstract = "Red blood cell (RBC) hydration is regulated in part by the Ca2+-activated K+ efflux (Gardos) channel. Senicapoc selectively blocks potassium efflux through the Gardos channel, reducing RBC dehydration and haemolysis, and increasing haemoglobin levels in sickle cell disease (SCD). This randomized, placebo-controlled trial was designed to determine the safety and clinical efficacy of senicapoc in SCD patients. One hundred and forty-five patients were randomized to receive senicapoc and 144 patients to receive placebo for 52weeks. Consistent with a previous study, patients in the senicapoc group had significantly increased haematocrit, haemoglobin, and decreased numbers of both dense erythrocytes and reticulocytes when compared to the placebo group. The unblinded Data Monitoring Committee terminated this study early due to a lack of efficacy when it determined that, despite improvements in anaemia and haemolysis, no significant improvement in the rate of sickle cell painful crises was observed in patients treated with senicapoc compared to those on placebo (0·38 vs. 0·31, respectively). Comparisons of the times to first, second and third crises between the senicapoc and placebo groups were not statistically significant. Nausea and urinary tract infections occurred more frequently in the senicapoc group than placebo. Serious adverse events were similar in the two groups.",
author = "Kenneth Ataga and Marvin Reid and Ballas, {Samir K.} and Zahida Yasin and Carolyn Bigelow and James, {Luther St} and Smith, {Wally R.} and Frederic Galacteros and Abdullah Kutlar and Hull, {James H.} and Stocker, {Jonathan W.}",
year = "2011",
month = "4",
day = "1",
doi = "10.1111/j.1365-2141.2010.08520.x",
language = "English (US)",
volume = "153",
pages = "92--104",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease

T2 - A phase III randomized, placebo-controlled, double-blind study of the gardos channel blocker senicapoc (ICA-17043)

AU - Ataga, Kenneth

AU - Reid, Marvin

AU - Ballas, Samir K.

AU - Yasin, Zahida

AU - Bigelow, Carolyn

AU - James, Luther St

AU - Smith, Wally R.

AU - Galacteros, Frederic

AU - Kutlar, Abdullah

AU - Hull, James H.

AU - Stocker, Jonathan W.

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Red blood cell (RBC) hydration is regulated in part by the Ca2+-activated K+ efflux (Gardos) channel. Senicapoc selectively blocks potassium efflux through the Gardos channel, reducing RBC dehydration and haemolysis, and increasing haemoglobin levels in sickle cell disease (SCD). This randomized, placebo-controlled trial was designed to determine the safety and clinical efficacy of senicapoc in SCD patients. One hundred and forty-five patients were randomized to receive senicapoc and 144 patients to receive placebo for 52weeks. Consistent with a previous study, patients in the senicapoc group had significantly increased haematocrit, haemoglobin, and decreased numbers of both dense erythrocytes and reticulocytes when compared to the placebo group. The unblinded Data Monitoring Committee terminated this study early due to a lack of efficacy when it determined that, despite improvements in anaemia and haemolysis, no significant improvement in the rate of sickle cell painful crises was observed in patients treated with senicapoc compared to those on placebo (0·38 vs. 0·31, respectively). Comparisons of the times to first, second and third crises between the senicapoc and placebo groups were not statistically significant. Nausea and urinary tract infections occurred more frequently in the senicapoc group than placebo. Serious adverse events were similar in the two groups.

AB - Red blood cell (RBC) hydration is regulated in part by the Ca2+-activated K+ efflux (Gardos) channel. Senicapoc selectively blocks potassium efflux through the Gardos channel, reducing RBC dehydration and haemolysis, and increasing haemoglobin levels in sickle cell disease (SCD). This randomized, placebo-controlled trial was designed to determine the safety and clinical efficacy of senicapoc in SCD patients. One hundred and forty-five patients were randomized to receive senicapoc and 144 patients to receive placebo for 52weeks. Consistent with a previous study, patients in the senicapoc group had significantly increased haematocrit, haemoglobin, and decreased numbers of both dense erythrocytes and reticulocytes when compared to the placebo group. The unblinded Data Monitoring Committee terminated this study early due to a lack of efficacy when it determined that, despite improvements in anaemia and haemolysis, no significant improvement in the rate of sickle cell painful crises was observed in patients treated with senicapoc compared to those on placebo (0·38 vs. 0·31, respectively). Comparisons of the times to first, second and third crises between the senicapoc and placebo groups were not statistically significant. Nausea and urinary tract infections occurred more frequently in the senicapoc group than placebo. Serious adverse events were similar in the two groups.

UR - http://www.scopus.com/inward/record.url?scp=79952594455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952594455&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2010.08520.x

DO - 10.1111/j.1365-2141.2010.08520.x

M3 - Article

VL - 153

SP - 92

EP - 104

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -